Evaluating and treating anxiety disorders in medical settings

Journal of Postgraduate Medicine

Volumn 48, Issue 4, 2002, Pages 317-321

  Ball, S ^a   Goddard, A ^a   Shekhar, Anantha ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety disorders; Medical comorbidity; Treatment of anxiety

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; BUSPIRONE; CHLORDIAZEPOXIDE; CITALOPRAM; CLONAZEPAM; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OXAZEPAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ANXIETY DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG HALF LIFE; DRUG SAFETY; EVALUATION; HEPATITIS; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; MEDICAL LITERATURE; PREVALENCE; PRIMARY MEDICAL CARE; REVIEW; TREATMENT OUTCOME;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; COMORBIDITY; HUMANS;

EID: 0036819783     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Sherbourne CD, Jackson CA, Meredith LS, Camp P, Wells KB. Prevalence of comorbid anxiety disorders in primary care outpatients. Arch of Fam Med 1996;5:27-34.
2. Cassem EH. Depression and anxiety secondary to medical illness. Psychiatr Clin of North Am 1990;13:597-612.
3. Eagger S, Luxom LM, Davies RA, Coelho A, Ron MA. Psychiatric morbidity in patients with peripheral vestibular disorder: A clinical and neuro-otological study. J Neurol Neurosurg Psychiatry 1992; 55:383-7.
4. Frasure-Smith N, Lesperance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: Is it more than depression? Health Psychology 1995;14:388-98.
5. Sherbourne CD, Wells KB, Meredith LS, Jackson CA, Camp P. Comorbid anxiety disorder and the functioning and well-being of chronically ill patients of general medical providers. Arch Gen Psychiatry 1996;53:889-95.
6. Marcus SC, Olfson M, Pincus HA, Shear MK, Zarin DA. Self-reported anxiety, general medical conditions, and disability bed days. Am J Psychiatry 1997;154:1766-8.
7. Wise MG, Rieck SO. Diagnostic considerations and treatment approaches to underlying anxiety in the medically ill. J Clin Psychiatry 1993;54:22-6.
8. Marsh CM. Psychiatric presentations of medical illness. Psychiatr Clin of North Am 1997;20:181-204.
9. Reiss, S. Expectancy model of fear, anxiety, and panic. Clin Psychol Rev 1991;11:141-53.
10. Cox, BJ, Parker, JDA, Swinson, RP. Anxiety sensitivity: confirmatory evidence for a multidimensional construct. Behav Res Ther 1996; 34:591-8.
11. Barsky AJ, Ahern DK, Brener J, Surman OS, Ring C, Dec GW. Palpitations and cardiac awareness after heart transplantation. Psychosom Med 1998;60:557-62.
12. Gorman JM, Kent JM. SSRIs and NSRIs: Broad spectrum of efficacy beyond major depression. J Clin Psychiatry 1999;60(Suppl 4):33-8.
13. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(Suppl 1):1-21.
14. Sheehan DV. Attaining remission in generalized anxiety disorder: Venlafaxine extended release comparative data. J Clin Psychiatry 2001;62(Suppl 19):26-31.
15. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders [see comments]. N Engl J Med 1993;328:1398-405.
16. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early co-administration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001;58:681-6.
17. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20:467-71.